AstraZeneca posts 7% Q3 revenue growth, beats forecasts and launches $2 bn restructuring plan

AstraZeneca reported third‑quarter 2026 revenue of $16.21 billion, up 7% at constant exchange rates, and core earnings per share of $2.79, up 19% (19). The company reaffirmed its FY 2026 guidance for mid‑to‑high single‑digit revenue growth and low double‑digit core EPS growth (19). It announced a restructuring programme with up‑to‑$2 billion of one‑time charges designed to deliver $1.5 billion of annual pre‑tax savings that will be reinvested in the drug pipeline (19). In the same quarter it completed a $2 billion equity investment in Summit Therapeutics, giving it roughly a 12% equity stake (2).

The results beat analyst expectations and the guidance reaffirmation supports the company’s growth outlook, as noted in the earnings release (19). The $1.5 billion annual savings plan is intended to fund pipeline development, potentially enhancing future revenue and margins (6).

  • 1Q3 2026 revenue was $16.21 billion, a 7% increase at constant exchange rates.
  • 2Core EPS for the quarter was $2.79, up 19% at constant rates.
  • 3Core operating profit rose to $5.86 billion, a 20% increase.
  • 4Global Farxiga sales fell 25% to $1.61 billion.
  • 5The restructuring programme will incur up to $2 billion of one‑time charges and is expected to generate $1.5 billion of annual pre‑tax savings.
  • 6AstraZeneca completed a $2 billion equity investment in Summit Therapeutics, acquiring roughly a 12% equity stake.

Sources